Healthcare ❯ Pharmaceuticals

Cancer Treatment

Keytruda Drug Approval Clinical Trials Drug Development Oncology Bladder Cancer Gastrointestinal Stromal Tumors FDA Approval Darzalex Innovation Personalized Cancer Treatment Drug Management Innovative Therapies Chemotherapy Zytostatika Bispecific Antibodies Rare Tumors Acute Myeloid Leukemia Radioconjugates Lung Cancer CAR-T Therapy Billing Fraud Pancreatic Cancer Opdivo Rare Tumours Prostate Cancer Sales Performance Monoclonal Antibodies Cytostatics Advanced Therapies ISB 2001 Medication Supply Bladder Cancer Drugs

Regeneron Tops Q1 Estimates as Dupixent and Libtayo Outpace Eylea

Growth outside eye care offset pressure on Eylea.

Can-Fite's Namodenoson Clears Phase IIa Safety Bar in Pancreatic Cancer

Barclays Starts Merck at Overweight on 2026 Pipeline Catalysts as WSJ Reports Business Split Plan

Merck Ends Revolution Medicines Takeover Talks After Valuation Standoff

Merck Lifts Mid-2030s Revenue Goal to $70 Billion From Emerging Businesses

Bristol Myers Enters 2026 With Eliquis Medicaid Pact, Opdivo Qvantig Rollout, and Divergent Analyst Views

Crescent, Kelun-Biotech Trade Cancer Asset Rights in Cross-Border Deal as Crescent Secures $185 Million